FindTrial
Sign In

A Real-World Study of Bispecific Antibodies in Multiple Myeloma

A Real-World Study of Bispecific Antibodies, Teclistamab and Elranatamab, for Patients With Multiple Myeloma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06359067
Acronym
BISPEMM
Enrollment
600
Registered
2024-04-11
Start date
2022-07-01
Completion date
2023-12-31
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Multiple myeloma, Teclistamab, Elranatamab, Bispecific antibody

Brief summary

Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP).

Detailed description

Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP).

Interventions

OTHERTreated by bispecific antibodies, teclistamab or elranatamab in usual care

Treated by bispecific antibodies, teclistamab or elranatamab in usual care

OTHERNot treated by bispecific antibodies in usual care

Not treated by bispecific antibodies in usual care

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult ≥ 18 years old * Patients with multiple myeloma * Patients who received at least one administration of the following therapies: teclistamab, elranatamab

Exclusion criteria

\- Patients opposed to the collection of their personal data

Design outcomes

Primary

MeasureTime frameDescription
Infection rateUp to 18 monthsExplore the infection rate

Secondary

MeasureTime frameDescription
Global survivalUp to 18 monthsExplore the global survival
Progression-free survivalsUp to 18 monthsExplore the progression-free survivals

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026